However, previous GWAS studies have shown an association between genetic variants of GALNTL4 and protective effects against differentiated thyroid cancer [40], and GALNTL4 SNPs are reportedly associated with the cisplatin sensitivity of urothelial cancer [41] and the efficacy of gemcitabine combined with platinum in the chemo treatment of bladder urothelial carcinoma [42]. Here, GALNT18 is linked to thyroid cancer.